Mapi Pharma
Mapi Pharma is a privately held, clinical-stage biopharmaceutical company developing proprietary long-acting depot injectable formulations. Its lead asset, GA Depot (once-monthly glatiramer acetate), targets multiple sclerosis under an exclusive global license to Viatris, with an additional pipeline in CNS, metabolic, and oncology indications.
- Company typePrivate
- Founded2008
- HeadquartersNess Ziona, Israel
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Mapi Pharma does
Mapi Pharma Ltd. is a privately held, clinical-stage biopharmaceutical company founded in 2008 and headquartered in Ness Ziona, Israel, with manufacturing in Jerusalem and Neot-Hovav and R&D facilities in China and Germany. The company develops proprietary long-acting depot injectable formulations — extended-release microspheres delivering drug over periods ranging from weekly to monthly — built around a platform protected by granted US patents (notably 8,377,885 B2 covering glatiramer acetate depot through December 2030) and supported by GMP-approved API and aseptic fill-finish manufacturing capacity that includes a ~50,000 sq ft former J&J/Omrix sterile injectable plant in Jerusalem.
Mapi's lead product is GA Depot (glatiramer acetate depot), a 40 mg once-monthly intramuscular injection for relapsing and primary progressive multiple sclerosis. Phase III results in 1,016 RMS patients showed a 30.1% reduction in annualized relapse rate versus placebo, the FDA accepted the NDA in August 2023, and the asset is in final regulatory review in Germany ahead of a planned 2027/2028 EU launch. Global commercialization rights for GA Depot are licensed exclusively to Viatris (formerly Mylan), which has also invested $20 million as a strategic shareholder. The broader pipeline applies the depot platform to Cariprazine Depot (schizophrenia, Phase I/II), Semaglutide and Tirzepatide Depot (metabolic/GLP-1, Phase I/II initiated 2026), Anastrozole Depot (breast cancer), Deutetrabenazine Depot (Huntington's), and Paliperidone Palmitate, with co-development partner Zhejiang Jingxin holding rights for China.
Mapi generates minimal current revenue from select-region sales of generic Naltrexone, generic Fingolimod, and generic Apremilast; the primary monetization path is licensing, manufacturing supply, and royalties tied to GA Depot's commercial launch via Viatris, supplemented by geographic distribution partners (Gaelan Medical in UAE) and the Zhejiang Jingxin product development agreement. Pricing is not publicly disclosed and the company is not yet commercial for its lead asset.
Mapi Pharma firmographics
Firmographics- Name
- Mapi Pharma
- Legal name
- Mapi Pharma Ltd.
- Website
- https://mapi-pharma.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Mapi Pharma is a privately held, clinical-stage biopharmaceutical company developing proprietary long-acting depot injectable formulations. Its lead asset, GA Depot (once-monthly glatiramer acetate), targets multiple sclerosis under an exclusive global license to Viatris, with an additional pipeline in CNS, metabolic, and oncology indications.
- Ownership category
- akta.pro rank
Mapi Pharma industry classification
Industry- Product category
- Long-acting injectable pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
Keywords
Where Mapi Pharma is headquartered
LocationHeadquarters
- HQ city
- Ness Ziona
- HQ country
- Israel
- HQ region
- Middle East
Offices5 records
Markets served
Mapi Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- Pharmaceutical Product Sales: Revenue from sale of proprietary pharmaceutical products including GA Depot and generic versions of marketed drugs like Fingolimod (Gilenya) and Apremilast (Otezla) in select regions.
- Licensing and Partnership Revenue: Revenue from strategic partnerships including manufacturing and supply agreements with Viatris for GA Depot commercialization globally, and product development agreements with partners like Zhejiang Jingxin for Chinese market.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
Mapi Pharma product offering
Product offeringCore offering
Mapi Pharma develops proprietary long-acting depot injectables, complex active pharmaceutical ingredients, and pharmaceutical formulations for neurological, metabolic, oncology, and other chronic conditions. It also markets selected generic drugs and operates integrated GMP-approved API and finished-dosage-form manufacturing facilities.
Product overview
Mapi Pharma is a clinical-stage pharmaceutical company developing proprietary long-acting depot injectable drugs for lifecycle management of innovative and existing commercially successful pharmaceuticals. The company's lead product is GA Depot (Glatiramer Acetate Depot), a once-monthly injection for multiple sclerosis treatment partnered with Viatris and currently under FDA review. The pipeline includes multiple depot formulations across therapeutic areas: CNS disorders (Cariprazine Depot for schizophrenia, Pregabalin ER for neuropathic pain), metabolic diseases (Semaglutide Depot and Tirzepatide Depot for diabetes/weight management), and oncology (Anastrozole Depot for breast cancer). Mapi also markets generic versions of established drugs including Fingolimod (Gilenya), Apremilast (Otezla), and Naltrexone (Vivitrol). The company operates fully integrated R&D, clinical development, and GMP-approved manufacturing facilities in Israel.
Differentiator
Problem solved
Functional benefit
Products and services
- GA Depot (Glatiramer Acetate Depot) A once-monthly 40 mg intramuscular glatiramer acetate injection for relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS), reducing administration from daily or thrice-weekly Copaxone schedules to once every four weeks.
- Semaglutide Depot Long-acting injectable formulation of semaglutide for diabetes treatment, developed using Mapi's depot technology for once-monthly injection; currently in a Phase I/II study identified as ClinicalTrials.gov NCT07563699.
- Tirzepatide Depot Long-acting injectable formulation of tirzepatide (Mounjaro/Zepbound) for chronic weight management, developed using Mapi's depot technology.
- Anastrozole Depot Long-acting depot formulation of anastrozole (Arimidex) for adjuvant endocrine therapy to prevent recurrence in breast cancer, supported by Mapi intellectual property and pharmacokinetic modeling.
- Cariprazine Depot Long-acting depot injectable for schizophrenia treatment, enrolling in a Phase I/II study with positive pharmacokinetic results supporting planned Phase III initiation in 2027.
- Deutetrabenazine Depot Long-acting depot injectable for Huntington's disease.
- Naltrexone Generic (Vivitrol) AB-rated generic version of naltrexone (Vivitrol) for opioid dependence treatment.
- Fingolimod Generic (Gilenya) Generic version of fingolimod marketed under the Gilenya brand for multiple sclerosis treatment and sold in select regions.
- Apremilast Generic (Otezla) Generic version of apremilast marketed as Apremil 30 mg for psoriasis treatment and sold in select regions.
- Pregabalin ER Extended-release formulation of pregabalin (Lyrica) for the treatment of neuropathic pain and epilepsy.
- Paliperidone Palmitate Long-acting depot injectable for the treatment of schizophrenia.
- Buspirone ER Extended-release formulation of buspirone for the treatment of schizophrenia.
- Tapentadol Pain-relief medication indicated for moderate-to-severe acute pain treatment, developed using Mapi's process for cost-effective production.
Quantifiable outcome
- 30.1% reduction in annualized relapse rate (ARR) vs placebo in Phase III RMS study
- +2 more outcomes
Companies that use Mapi Pharma
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles4 records
Mapi Pharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Mapi Pharma partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered minor, flagship and core.
- Gaelan Medical Trade LLCminorExclusive marketing and distribution agreement for Mapi products in UAE market.
- Viatris (formerly Mylan)flagshipMylan acquired global marketing rights to GA Depot in 2018; FDA accepted NDA filing with PDUFA target date of March 8, 2024; Mapi supplies product for commercial sale globally. Partnership strengthened with additional $20M investment in June 2020.
- Zhejiang Jingxin Pharmaceutical Co.coreChinese pharmaceutical company invested $10M initially in 2016 and $10M in 2018 for total $20M; product development agreement where Mapi develops products exclusively for Jingxin for Chinese market registration, manufacturing and marketing. Co-development of products for schizophrenia, diabetes, and other depot injectable indications.
Scale indicators9 records
Recent moves10 records
Expansion highlights7 records
Mapi Pharma competitors and assessment
Company assessmentBroad incumbents
- Hikma Pharmaceuticals: Generic and specialty injectable pharma with a broad sterile injectable portfolio. Comparable on injectable manufacturing scale, complex generics expertise, and US/EU distribution reach relevant to Mapi's planned expansion.
- Novartis: Markets Gilenya (fingolimod) for MS, a key competing oral therapy to injectable GA Depot. Comparable as a CNS specialty pharma incumbent whose franchise Mapi's pipeline and platform directly challenge.
- Biogen: Major MS player (Tysabri, Avonex, Plegridy, Vumerity) and broader neuroscience biopharma. Comparable on CNS specialty pharma franchise development, large-scale MS clinical infrastructure, and neurology-focused commercial models.
- Viatris: Global commercialization partner for GA Depot and a broader specialty/generic pharma with its own MS franchise (Copaxone authorized generic). Comparable as a large-scale neurology and complex injectable commercialization platform relevant to Mapi's go-to-market.
- Roche: Markets Ocrevus, a leading high-efficacy MS therapy, and is expanding in progressive MS. Comparable as a broad incumbent whose MS franchise defines the competitive benchmark GA Depot must outperform in efficacy and adherence.
- Amneal Pharmaceuticals: US-focused specialty and complex generic injectable manufacturer with an AffaMed and global footprint. Comparable on high-barrier generic injectables strategy and sterile manufacturing capabilities relevant to Mapi's generic and depot portfolio.
Direct peers
- Tolmar Pharmaceuticals: Specialty pharma specializing in long-acting injectable depot technologies (e.g., Eligard for prostate cancer). Highly comparable on depot formulation know-how, sterile manufacturing, and urology/oncology injectable portfolio overlap.
- Teva Pharmaceutical Industries: Originator of Copaxone (daily glatiramer acetate) for MS and a fellow Israeli specialty/generic pharma. Teva is the incumbent Mapi must displace in the GA franchise, and its authorized generic makes it the closest clinical and commercial comparable.
- Heron Therapeutics: US specialty pharma built around long-acting injectable technology (Cinvanti, Sustol, Zynrelef). Closely comparable as a small-cap, depot/injectable-focused specialty pharma with similar capital and commercialization constraints.
Emerging players
- Polpharma Biologics: European biosimilars and complex injectables developer with MS-relevant programs (e.g., natalizumab biosimilar). Comparable as an emerging specialty injectables player targeting the same prescribers and patient pool as Mapi's GA Depot.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Mapi Pharma social profiles
Digital presenceMapi Pharma compliance and trust
Trust signalCompliance3 records
Mapi Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mapi Pharma leadership team
Management profileNumber of profiles
Profiles2 records
Mapi Pharma funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mapi Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mapi Pharma
What does Mapi Pharma do?
Mapi Pharma develops proprietary long-acting depot injectables, complex active pharmaceutical ingredients, and pharmaceutical formulations for neurological, metabolic, oncology, and other chronic conditions. It also markets selected generic drugs and operates integrated GMP-approved API and finished-dosage-form manufacturing facilities.
Is Mapi Pharma a public or private company?
Mapi Pharma is a private company. It is classified as venture growth investor backed and is currently operating.
When was Mapi Pharma founded?
Mapi Pharma was founded in 2008. It employs 11 to 50 people.
Where is Mapi Pharma based?
Mapi Pharma is headquartered in Ness Ziona, Israel, in the Middle East region.
How does Mapi Pharma make money?
Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing and Partnership Revenue.
Who are Mapi Pharma's main competitors?
Broad incumbents on record are Hikma Pharmaceuticals, Novartis, Biogen, Viatris, Roche and Amneal Pharmaceuticals. Direct peers are Tolmar Pharmaceuticals, Teva Pharmaceutical Industries and Heron Therapeutics. Polpharma Biologics is listed as an emerging player.
Does Mapi Pharma have an API?
No public API is recorded for Mapi Pharma.
What industry is Mapi Pharma in?
Mapi Pharma's product category is Long-acting injectable pharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.